top of page

Cancer Immunotherapy

Embryonic Stem Cells

Regenerative Bio Cell Cancer Immunotherapy

A Revolution against Cancer

According to The American Cancer Society, immunotherapy is a treatment that fights cancer using the body’s immune system. The fundamental mechanic of immunotherapy is destroying the shield that conceals a cancer cell from the immune system. This allows the immunity to perceive the shield as a foreign object and thus attacking it.

The immune system is then activated, while the anti-tumor activity of killer T-cells enhances their capacity to destroy cancer cells and provide a lasting anti-cancer impact.

Immunotherapy works by targeting the proteins on the surface of cancer cells; tumor-associated antigens.

It makes the immune system of the patient to identify and fight cancer cells, therefore, changing the growth of existing tumors, and possibly preventing new cancer cells from spreading.

The therapeutic vaccines aim to enhance the immunity’s capacity to recognize and destroy cancer cells, thus enabling the immune system to widen the attack. After vaccine stimulation, the immune system is as adaptable as cancer.

fgfcgcvJHHHHHHb.jpg

How Immunotherapy Works against Cancer?

Cancer cells survive mainly because they can hide from a patient’s system. Specific immunotherapies can identify cancer cells, making it easy for the immunity to discover and kill them. Others work by strengthening the immunity, in order to fight cancer better.

Advanced Cell Therapy?

Cancer vaccination or advanced cell immunotherapy is a technique of providing immunity cells activated in vitro, in cases where victims need sustained and efficient activation of the immunity. This is done to fight intratumorally or circulating cancer cells without affecting other cells in the body. It is a type of personalized and unique treatment for the molecular features of tumors.

How does Regenerative Bio Cell cancer Immunotherapy Work?

Before explaining the phases of  Regenerative Bio Cell treatment protocol, it is helpful to learn about processes, which play major roles in cancer immunotherapy and cancer vaccine simulations

fgfcgcvb.jpg

Activating Dendritic Cells using Antigens of the Tumor Cells

Dendritic cells are a unique type of cells that works by bringing together cytotoxic T lymphocytes and tumor antigens.

Therefore, they help assist the body in killing cancer cells. Dendritic cells usually are autologous; monocytes from cancer patients are changed to dendritic cells.

This helps the vaccine to be personalized and specific. The procedure of obtaining them is complicated. However, in a lab, monocytes are cultured using several cytokines and other growth factors in order to differentiate the cells into dendritic cells.

Antigens of every tumor, or rather signals from a tumor, are differentiated in every patient. Following this, dendritic cells are matured and stimulated with antigens from every patients’ malignant cells.

This helps the signal to be obtained more effectively and directly. Once cells develop, they are administered back to the patient subcutaneously around lymph nodes. The access of cells to lymph nodes is then facilitated, providing a site for the presentation of antigens.

gvb.jpg

Natural killer cells (NK Cells)

These are a type of lymphocytes that contain perforins and gramzyms, which are substances that destroy target cells, including infected cells and cancer cells.

Unlike dendritic cells, they have the uniqueness of not requiring cells that present antigen in order to function.

The lymphocytes can identify unwanted cells and link them using a series of proteins such as MHC 1.

This assists in obtaining the identification and destruction of target cells without interfering with the Natural Killer cells.

fg.jpg

Activated Cytotoxic Lymphocytes (LAK CELLS)

Natural killer cells and cytotoxic lymphocytes are specialized cells that damage the target cells.

Target cells can be cancer cells or infected cells. The killer cells mainly work through two mechanisms. First, they identify an outer surface of unwanted cells and release a protein known as perforin that perforates and cell membranes and kills the target cells.

Secondly, they provide other proteins called gramzyms, that alter the internal pH of unwanted cells, thereby destroying them. There are other common mechanisms, including one that activates caspases, a cascade of proteins. At the end of their activation, they result in apoptosis or the death of target cells.

The effectiveness of these cells is based on their activation. There are several trigger techniques, but the most common one is the use of cytokines or binding to dendritic cells.

Adoptive cell therapy refers to the use of such cells. It is an essential part of our program. Cancer patients are given a combination of natural killer cells, activated cytotoxic cells, and dendritic cells, thereby enhancing the anti-tumor response of the patients.

DFDF.jpg

Phases of Regenerative Bio Cell Cancer Immunotherapy

When deciding a treatment method for cancer patients, all the aspects and factors that surround and affect the progression and generation of tumor cells must be taken into account.

Some traditional treatment methods damage tumor burdens, but in some cases, they change the environment surrounding the tumor and may enhance cell embolization past the destruction of the tumor burden.

This may lead to metastatic illness, with radio or chemo resistance, which makes it hard to treat cancer. However, when all these factors are accounted for, and when therapies are more targeted and personalized, the anticipated outcome should be the regulation of tumor progression and enhanced survival of cancer patients.

Our program falls into the following four phases;

Evaluation phase – This is where the patient is reviewed molecularly, physically, and metabolically. Special attention is given to the diagnosis of other conditions that might accelerate or change the survival capacity of patients.

Conditioning – This is our second phase and involves correcting protein deficiencies. Here, unique nutrients that exhibit invitro impact on cancerous cells are provided, which helps in enhancing the activation of the immune system. In this phase, the appropriate detoxification process is undertaken. The infectious foci are removed while the cells blocking the immunity response are diminished.

Immune system activation – The third phase involves the proliferation and activation of the immune system cells that are charged with destroying malignant cells. These procedures are undertaken in vitro and then administered to patients.

Usually, patients do not experience clinical events of rejection or side effects, since the cells are their own. This is the most essential phase in the program

The cellular immunotherapy is held together with the natural killer cells, a cocktail of autologous cytokine, activated cytotoxic lymphocytic cells, and the dendritic cells, which helps in activating the immune system.

Maintenance – This is our fourth and final stage. In this phase, patients keep activating the immune system according to the autologous cytokines.

It also involves sustaining the balance of cell proliferation using the natural agents from the vitro effect in the destruction of circulating cancerous cells. The immune system of different patients will respond differently.

Since every patient will exhibit varying clinical responses to treatment, each is personally and individually evaluated together with their circulating cell count, the number of lymphocytic Regulatory T cells, and other considerations.

Immune Activation Efficiency

The effectiveness of the Immune System Activation can be evaluated from various aspects; it can be clinical, through laboratory tests, serological tests, CT scans, histopathological, or dynamic in vivo

Phases of Regenerative Bio Cell Cancer Immunotherapy

When deciding a treatment method for cancer patients, all the aspects and factors that surround and affect the progression and generation of tumor cells must be taken into account.

Some traditional treatment methods damage tumor burdens, but in some cases, they change the environment surrounding the tumor and may enhance cell embolization past the destruction of the tumor burden.

This may lead to metastatic illness, with radio or chemo resistance, which makes it hard to treat cancer. However, when all these factors are accounted for, and when therapies are more targeted and personalized, the anticipated outcome should be the regulation of tumor progression and enhanced survival of cancer patients.

Our program falls into the following four phases;

Evaluation phase – This is where the patient is reviewed molecularly, physically, and metabolically. Special attention is given to the diagnosis of other conditions that might accelerate or change the survival capacity of patients.

Conditioning – This is our second phase and involves correcting protein deficiencies. Here, unique nutrients that exhibit invitro impact on cancerous cells are provided, which helps in enhancing the activation of the immune system. In this phase, the appropriate detoxification process is undertaken. The infectious foci are removed while the cells blocking the immunity response are diminished.

Immune system activation – The third phase involves the proliferation and activation of the immune system cells that are charged with destroying malignant cells. These procedures are undertaken in vitro and then administered to patients.

Usually, patients do not experience clinical events of rejection or side effects, since the cells are their own. This is the most essential phase in the program

The cellular immunotherapy is held together with the natural killer cells, a cocktail of autologous cytokine, activated cytotoxic lymphocytic cells, and the dendritic cells, which helps in activating the immune system.

Maintenance – This is our fourth and final stage. In this phase, patients keep activating the immune system according to the autologous cytokines.

It also involves sustaining the balance of cell proliferation using the natural agents from the vitro effect in the destruction of circulating cancerous cells. The immune system of different patients will respond differently.

Since every patient will exhibit varying clinical responses to treatment, each is personally and individually evaluated together with their circulating cell count, the number of lymphocytic Regulatory T cells, and other considerations.

Immune Activation Efficiency

The effectiveness of the Immune System Activation can be evaluated from various aspects; it can be clinical, through laboratory tests, serological tests, CT scans, histopathological, or dynamic in vivo

f.jpg

Our center evaluated 29 patients with various types of solid tumors receiving Cellular Immunotherapy; the blue bars show the amount of CTC (Circulating Tumor Cells) that patients had in their circulation at the time of arrival to the program, the red bars show the count of CTC patients presented at the end of Autologous Immunotherapy

Patient 13 and patient 21, showed an increase on this cells after treatment, both of which were from patients who had recently undergone chemotherapy and were both hematological malignancies, which makes evaluation somewhat difficult with this method, these cases especially were evaluated with blood blast sand in both there was a decrease

Our assessment of effectiveness is based directly in vitro, with the patient’s cells dynamically alive, where morphologically they are evaluated as specific cells and that these cells also release proteins or substances that indicate they are activated these substances are measured in the laboratory thereby we confirm their activation.

Patients are evaluated with the Scale RECISTR a dialogically with:

  • Complete Response.

  • Partial Response.

  • Progressive Disease

  • Stabilization of the Disease

Screen Shot 2020-08-13 at 1.54.52 AM.png

The graphic shows the expansion of cytotoxic lymphocytes incubated with I L-2 from our cultures, the blue lines shows the level of total lymphocytes that patients had on admission to the cellular immunotherapy program, the red line indicates cell proliferation at 24 hours of culture, and finally the green line indicates cell expansion at 48 hours of culture, showing that the immune system of cancer patients respond to activation with cytokines in vitro environments.

ihh.jpg

Tijuana Mexico

 

Less than 25 minutes from San Diego, California, you will find beautiful Tijuana, Mexico. Conveniently located just across the border between the United States and Mexico, Tijuana is the ideal destination for your treatment. If you are interested in combining luxury with medical service, then our advanced cancer center in Tijuana may be right for you.

Cancer Center

  • State of art facility equipped with the latest technology.

  • A futon for your support companion or relative´s comfort.

  • Wireless Internet.

  • Bilingual nursery and medical doctors on site 24/7.

  • Your personal valet is dedicated to meeting the needs of yourself and a travel companion through your stay with us.

  • Convenient location: Safe locality, close to restaurants, hotels and tourist district.

  • Located 35 minutes from the San Diego Airport, where our drivers pick you up.

lkhhjno.jpg

Accommodations

All Hotel Rooms feature the following amenities:

  • GYM

  • 24-hour room service

  • Car rental support

  • Concierge service

  • 24-hour taxi service

  • Business Center

  • Wireless Internet

  • Restaurant & Bar

HOTEL LUCERNA TIJUANA

After having performed the cancer procedure, patients will leave the hospital and will be taken to their hotel room at Lucerna Hotel, for the ultimate medical tourism experience.

The hotel room will be shared with another patients, if any of the patients want a single room they must pay the difference of the price.

HOTEL INFORMATION:

Address:    Paseo de los Héroes #10902, Zona Rio Tijuana, B.C. 22320
Phone:        01 800 026 6300
Website:    https://www.hoteleslucerna.com/tijuana/

bottom of page